Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. (Q37444920)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

F Lefranc

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

M Rynkowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

O DeWitte

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

R Kiss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

Advances and Technical Standards in Neurosurgery

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

3-35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

Nuclear factor-kappaB: the enemy within

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

ADF/cofilin and actin dynamics in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The TOR pathway: a target for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Na,K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Galectin-1: a small protein with major functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Patterns of care for adults with newly diagnosed malignant glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

DRAM, a p53-induced modulator of autophagy, is critical for apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Tumour stem cells and drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Ion transport proteins anchor and regulate the cytoskeleton

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Repression of Na,K-ATPase beta1-subunit by the transcription factor snail in carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The coordinate regulation of the p53 and mTOR pathways in cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Making a tumour's bed: glioblastoma stem cells and the vascular niche.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The Treatment of Malignant Gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Regulation and function of aquaporin-1 in glioma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Development of matrix metalloproteinase inhibitors in cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Surgical management of high-grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

p53, Autophagy and tumor suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

[Dendritic cells and gliomas: a hope in immunotherapy?].

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Current and Future Gene Therapy for Malignant Gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The role of autophagy in cancer development and response to therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Incorporating molecular tools into clinical trials and treatment for gliomas?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Autophagy, the Trojan horse to combat glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Present and potential future issues in glioblastoma treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Autocrine glutamate signaling promotes glioma cell invasion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Self-eating and self-killing: crosstalk between autophagy and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Cancer: survival pathways meet their end.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Glutamate modulates sodium-potassium-ATPase through cyclic GMP and cyclic GMP-dependent protein kinase in rat striatum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

A role for caveolae in cell migration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Glioblastoma multiforme: evidence-based approach to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Pathways of apoptotic and non-apoptotic death in tumour cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Editorial: what is new in the treatment of gliomas?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Lessons learned in the development of targeted therapy for malignant gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Intravenous, non-viral RNAi gene therapy of brain cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Bcl-2 inhibition of autophagy: a new route to cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Gefitinib in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Inhibition of angiogenesis as a therapeutic strategy against brain tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Volume-activated chloride currents contribute to the resting conductance and invasive migration of human glioma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

The emerging role of anti-angiogenic therapy for malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Autophagy in the eukaryotic cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Chemotherapeutic approaches for targeting cell death pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Phase II trial of gefitinib in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Neural stem cells and the origin of gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

AMOG/beta2 and glioma invasion: does loss of AMOG make tumour cells run amok?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

SIK1 is part of a cell sodium-sensing network that regulates active sodium transport through a calcium-dependent process

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

31 March 2020

Cardenolides and cancer

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Glutamate release promotes growth of malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Apoptotic pathways and therapy resistance in human malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Na+-K+--ATPase-mediated signal transduction: from protein interaction to cellular function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-78741-0_1

10.1007/978-3-211-78741-0_1

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19368079%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference